Travere Therapeutics (TVTX) Amortization of Deferred Charges (2014 - 2022)

Travere Therapeutics has reported Amortization of Deferred Charges for 9 years, with the latest figure at $428000.0 in Q4 2022.

• For the quarter ending Q4 2022, Amortization of Deferred Charges fell 85.17% year-over-year to $428000.0; the trailing twelve-month figure through Dec 2022 stood at $1.6 million (down 73.28% YoY), and the FY2025 full-year result was $1.6 million, down 4.93% from the prior year.
• Amortization of Deferred Charges for Q4 2022 stood at $428000.0, roughly flat from $428000.0 in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $2.9 million in Q4 2021, with the low at $50000.0 in Q3 2018.
• Historically, Amortization of Deferred Charges has averaged $1.2 million across 5 years, with a median of $428000.0 in 2022.
• Annual changes were most pronounced in 2019 — Amortization of Deferred Charges soared 348.0% — and 2022, when it plunged 87.65%.
• Travere Therapeutics' Amortization of Deferred Charges stood at $2.4 million in 2018, then climbed by 3.64% to $2.5 million in 2019, then climbed by 7.3% to $2.7 million in 2020, then gained by 7.33% to $2.9 million in 2021, then plunged by 85.17% to $428000.0 in 2022.
• The last three Amortization of Deferred Charges figures came in at $428000.0 (Q4 2022), $428000.0 (Q3 2022), and $429000.0 (Q2 2022), per Business Quant data.